Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain

 

• Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issue
• CYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substance
• Kernel Flow pivotal in developing most accurate, effective treatment regimens for patients

The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health has become even more pressing now, with many companies committed to offering relief to the nearly 1 billion people worldwide who deal with mental-health issues. Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to progressing psychedelics to therapeutics, is making major progress in that direction based on pilot results from a recent study evaluating a proprietary neuroimaging technology (https://nnw.fm/b7Q0c). 

“In our national survey on mental health and coronavirus, we found that the COVID-19 pandemic has affected the mental health of 59% of people in the United States,” reported a recent SingleCare article (https://nnw.fm/OmesF). “Dismantling the stigma around mental illness is important now more than ever.”

SingleCare reported that an estimated 970 million people worldwide have a mental-health or substance-abuse disorder, with anxiety being the most common mental illness in the world, impacting 284 million people. Other significant mental-health challenges that are leading causes of serious disabilities include major depression, anxiety, alcohol-use disorders, schizophrenia, bipolar disorder, and dysthymia, or persistent mild depression. 

Cybin has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. Most recently the company announced that pilot results from its sponsored feasibility study evaluating Flow, Kernel’s quantitative neuroimaging technology, indicate that ketamine-induced changes in the brain’s functional connectivity persisted for several days after receiving the substance. 

“Kernel’s Flow technology is revolutionary in the field of brain imaging as it is the first easy-to-use wearable that can collect real-time brain activity before, during and after a psychedelic experience,” said Doug Drysdale, Chief Executive Officer of Cybin. “Previously, studies had to rely on subjective patient reporting. By utilizing Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics.

“Measuring where and how psychedelics work in the brain unlocks new frontiers of discovery in this space,” continued Drysdale. “Most importantly, Kernel Flow will enable us to measure the duration of effect during a psychedelic experience, which will be pivotal in developing the most accurate and effective treatment regimens for patients. This technology is precisely what we need to accelerate the development of psychedelics into therapeutics.”

The purpose of the four-week study is to evaluate the altered state of consciousness of an individual following the administration of ketamine. The Kernel Flow headset facilitates this; the system is equipped with hi-tech sensors that record brain activity and report a participant’s experience using structured questionnaires and validated assessments during study visits and at follow-up. Cybin and Kernel signed a partnership agreement in January 2021 that gives Cybin exclusive interest in any innovations discovered or developed through the company’s independent analysis of the study findings, while Kernel retains the same rights relating to its Kernel technology.

“Kernel Flow is a groundbreaking neuroimaging technology that enables rigorous characterization and quantification of physiological processes in the human brain,” said Kernel founder and CEO Bryan Johnson. “We’re excited to report the pilot results of a longitudinally rich dataset of brain activity before, during a ketamine-induced altered-state experience, and after. The quality of the data recorded with Flow may lead to a better understanding of the neuro effects from psychedelics on the brain and help to advance these powerful new therapies for patients.”

Cybin is currently working on three active drug programs: CYB003 targets major depressive disorder and alcohol use disorder, CYB004 is focused on anxiety disorders and CYB005 is studying neuroinflammation. The company has completed more than 140 preclinical studies and is making steady progress toward FDA IND filings; in addition, Cybin has developed 50 novel compounds and completed more than 10 patent filings across three patent families. 

The company is collaborating with a network of world-class partners and internationally recognized scientists as it progresses on its mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. 

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

Odyssey Group International Inc. (ODYY) Is ‘One to Watch’

 

• Odyssey boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices
• The company is evaluating PRV-002 for the treatment of concussion, a dramatically underserved indication that currently has no FDA-approved drug
• With PRV-001, Odyssey aims to receive Orphan Drug designation, which could potentially accelerate its pathway to FDA approval and provide seven years of market exclusivity
• CardioMap(R) is intended to provide early, non-invasive testing for heart disease and is being developed for a 510(k) regulatory pathway
• Save-A-Life is a developmental anti-choking device that Odyssey expects to position as the “accepted” standard and leader in the treatment of choking incidents
• The company’s sports advisory board is headlined by NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach
• Odyssey is guided by a senior management team with significant experience relating to refining acquired technologies, building commercial systems and forging strategic partnerships

Odyssey Group International (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

• PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.

PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (“CTE”).

• PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.

Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

• CardioMap(R) is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.

When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.

• Save-A-Life (“SAL”) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.

Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

For more information, visit the company’s website at 

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://nnw.fm/ODYY

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

Crypto Enthusiasts to Gather in Austin, TX for Four-Day 2022 Consensus Festival, Featuring Everything from Blockchain to Web3

 

• Hosted by CoinDesk, the 2022 Consensus festival is slated for June 9-12, 2022, in Austin, Texas
• The festival features 15,000+ attendees, 400+ speakers, and 250+ event sponsors, catering to all sides of blockchain, crypto, Web3, NFTs and the Metaverse
• Web3 is the future of the internet – creating a decentralized technology that removes the control from the big tech companies and places it back in the hands of the users
• Venture Capitalist firm Andreessen Horowitz announced a $4.5 billion fund aimed at Web3; with one third of the funds dedicated exclusively to seed deals
• Coinbase has become the first crypto-based company to be listed on the Fortune 500, making history as the first of its kind to make the list

As worldwide interest in cryptocurrency grows, so do the conventions dedicated to the sector. One of the largest and longest-running crypto-focused events, the 2022 Consensus festival hosted by CoinDesk, will take place June 9-12, 2022, in Austin, Texas, and is expected to feature all sides of blockchain, crypto, Web3, NFTs and the Metaverse. Consensus aims to create a one-of-a-kind experience on how crypto is remaking the worlds of finance, investing, culture, entertainment, marketing, governance and more.

For four days, thousands of attendees will get the opportunity to listen to more than 400 speakers from the industry. There will also be networking events scheduled throughout the festival, allowing more intricate connections to be made amongst guests, speakers and over 250 sponsors. Tickets for the event are still available at https://www.coindesk.com/consensus2022/.

The cryptocurrency industry changes constantly, and so do the power players in the market. For example, Coinbase (NASDAQ: COIN), a leading cryptocurrency exchange platform in the United States, has made history as the first cryptocurrency company to break into the Fortune 500. Despite the recent struggles to meet analyst expectations, the company achieved significant results in 2021, catapulting it onto the prestigious list at number 437 (https://nnw.fm/gNLHV).

Although 2021 seemed to be a good year for the crypto industry, the start of 2022 has proven difficult for most of the market. With Bitcoin’s market cap lingering around $1.31 trillion and a devastating crash of the Terra stablecoin – the industry seems to be stuck in a holding pattern, waiting for the next shoe to drop. Even with such a gloomy overcast on the crypto world, not all venture capitalists are using the same wait-and-see philosophy.

Silicon Valley venture capital firm Andreessen Horowitz has closed on its newest crypto fund ($4.5 billion), doubling its previous funding round. The fund highlights the widening interest of the firm’s limited partners in increasing their exposure to crypto startups. The firm has specified that one-third of this massive fund will be specifically earmarked for seed deals exclusively. One area of general interest is the Web3 future – which many are willing to spend the funding for despite recent turbulence in the industry (https://nnw.fm/ccHPL). 

The Web3 protocol has been in the making and on the radar of venture capitalists for quite a while. Back in the fall of 2021, Chris Dixon, a partner of Andreessen Horowitz, wrote: “We are now at the beginning of the Web3 era, which combines the decentralized, community-governed ethos of Web1 with the advanced, modern functionality of Web2.” 

The Web3 concept will take the power of the internet out of the hands of the big tech companies and place it back into the hands of the users utilizing blockchain technology (https://nnw.fm/13Ug6). Like cryptocurrency decentralizes finance, the Web3 protocol would decentralize technology – taking the ownership of the internet out of the hands of big companies like Google/Alphabet Inc. (NASDAQ: GOOG), Amazon.com, Inc. (NASDAQ: AMZN), and Facebook/Meta Platforms, Inc. (NASDAQ: FB), leading to the creation of what proponents describe as an egalitarian internet.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

Nowigence Inc. Knowledge Management Tool Distinguishes Itself by Offering Ability to Gather, Organize and Communicate Data

 

• A key to becoming “irreplaceable” is to communicate clearly, Inc. article suggests
• Nowigence believes the capability to communicate clearly can be found in its high-proprietary, cloud-based knowledge management tool: Pluaris
• Pluaris reads and analyzes information across the internet 24/7, then organizes and optimizes gathered data for storage, analysis, synthesis and retrieval

As companies — and individuals — work to make themselves irreplaceable, an Inc. newsletter notes that communicating clearly is a key skill (https://nnw.fm/YHw9x). Nowigence’s Pluaris, a high-proprietary, cloud-based knowledge management tool, makes clear communication easier than ever before.

One solution, the article points out, is to distinguish yourself — or your company — from the competition by communicating clearly. “Every job requires clear communication,” the article states. “A carpenter needs to explain clearly to the rest of the team what he’s doing and when he’s doing it. The sales [team] needs to broadcast the company’s unique [selling] points and draw leads to the close. The owner of the business needs to set targets and expectations so that team members know exactly what they have to do and customers know exactly what they’re getting.”

The capability to communicate clearly is rooted first in the ability to gather and organize information in an accessible, concise manner and then share that information with key individuals or organizations in a single, accessible platform. When an individual can do that, critical information is received, understood and acted upon, and the conveyors of that information become essential team members.

Professional knowledge workers who are responsible for researching, studying and sharing information with others and lifelong learners alike will be thrilled with Nowigence’s Pluaris and its ability to read and analyze information across the internet 24/7. Once this information is gathered, Pluaris then uses exclusive machine learning and natural language processing techniques to analyze the content; transform, link and taxonomize data; and then optimize for storage, analysis, synthesis and retrieval. 

This complete and thorough process results in information that provides answers, connections, notes and insight. And just as importantly, Pluaris provides a single platform so that all this critical information can be clearly and concisely communicated with others, allowing teams to work collaboratively from anywhere in the world as they discuss problems, identify solutions and make decisions.

For more information, visit the company’s website at www.Nowigence.com.

NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://nnw.fm/NOW

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork